tbuckley/cabot-search huggingface dataset:
PTH-011 Defining the optimal i-scan settings for small colonic polyp characterisation – results from a large prospective series: Abstract PTH-011 Table 1
Authors: PJ Basford, G Longcroft-Wheaton, P Bhandari
Journal: Gut (2015)

<h3>Introduction</h3> Characterisation of small colonic polyps has been identified as a key goal for advanced imaging modalities by the ASGE and ESGE. Pentax i-Scan is an endoscopic digital contrast technology shown to be an accurate tool for characterising small colonic polyps in-vivo. I-Scan combines features which accentuate dark-light borders (surface and contrast enhancement, SE/CE) and suppression of red light whist enhancing blue/green light (tone enhancement, TE). The optimal settings for use of i-Scan in the colon have yet to be determined. <h3>Method</h3> High quality digital images of 100 small colonic polyps were recorded as part of a prospective study (NCT 01761279). Images of each polyp were recorded in 3 i-Scan modes: i-Scan 1 (SE/CE), i-Scan 2 (TE) and i-Scan 3 (SE/CE/TE). Randomised images were viewed by 2 blinded endoscopists who rated visibility of diagnostic features and predicted polyp histology (neoplastic vs non-neoplastic). <h3>Results</h3> The proportion of adenomas rated as having visible pericryptal vessels were 59%, 81% and 82% for i-Scan 1, 2 and 3 respectively. The differences between i-Scan 1 and 2 (P = 0.001) and i-Scan 1 and 3 (P &lt; 0.001) were statistically significant. The difference in proportion of adenomas with no visible surface pattern between i-Scan 1 and 2 was statistically significant (26% vs 8%, P = 0.001), as was the difference between i-Scan 1 and 3 (26% vs 9%, P = 0.003). There was no significant difference between i-Scan 2 and 3 (8% vs 9%, P = 1.00). Mean sensitivity for adenomatous histology between the two endoscopists was 69% for polyps viewed with i-Scan 1. Compared to i-Scan 1 assessments sensitivity was significantly higher with i-Scan 2 (86%, P = 0.006 for comparison), and with i-Scan 3 (87%, P = 0.003 for comparison). There was no significant difference in sensitivity between i-Scan 2 and i-Scan 3 assessments (86% vs 87%, P = 1.000). No significant differences in specificity were found between the 3 i-Scan modes (i-Scan 1 vs i-Scan 2 P = 0.828, i-Scan 1 vs i-Scan 3 P = 1.000, i-Scan 1 vs i-Scan 3 P = 1.000). Overall accuracy increased from 79% with i-Scan 1 to 86.5% with i-Scan 2 and 87.5% with i-Scan 3. There was no significant difference in overall accuracy between i-Scan 1 and i-Scan 2 (P = 0.063) or i-Scan 2 and i-Scan 3 (P = 0.882). However there was a significant difference between i-Scan 1 and i-Scan 3 assessments (P = 0.032). <h3>Conclusion</h3> Tone enhancement appears to be the most effective component of the i-Scan system for accurate small colonic polyp characterisation, with no additional benefit from the addition of surface/contrast enhancement. <h3>Disclosure of interest</h3> None Declared.
GW27-e0505 Echocardiography-guided percutaneous per-apical laser ablation of ovine ventricular septum --- mid-term effects
Authors: Sun Chao, Jianli Fu, Guangbin He, Rui Hu, Fang Liu, Ruiqi Guo, Chuang Ye, Jianguo He, Liwen Liu, Liu liwen
Journal: Journal of the American College of Cardiology (2016)
Lymphoma and Chromosomal Instability in Artemis Deficient Mice - A Challenge for Long Term Malignancy Free Survival and Choice of Optimal Conditioning Regimen in Artemis Gene Therapy Trials.
Authors: Julia Hauer, Fatine Benjelloun, Serge Romana, Marc Lelorc’h, Alain Fischer, Jean-Pierre Villartay de, Marina Cavazzana-Calvo
Journal: Blood (2007)
Molecular Analysis of β-Thalassemia Cases in Poland.
Authors: Ewa Zdebska, Beata Burzynska, Ewa Mendek-Czajkowska, Malgorzata Maciag, Angelika Krawcewicz, Urszula Mokras, Anna Adamowicz-Salach, Jerzy Koscielak
Journal: Blood (2005)
TCT-336 Predictors of plaque progression in hypertensive angina patients with achieved low density lipoprotein cholesterol less than 70 mg/dL after rosuvastatin treatment
Authors: Young Joon Hong, Yohan Ku, Myung Ho Jeong, Min Chul Kim, Hyun Kuk Kim, Keun Ho Park, Doo Sun Sim, Ju Han Kim, Youngkeun Ahn
Journal: Journal of the American College of Cardiology (2015)
Lactate Dehydrogenase (LDH) Level Predicts the Outcome of Patients with Acute Myelogenous Leukemia (AML) Following HLA-Matched Sibling Bone Marrow Transplant (BMT).
Authors: Matt Kalaycio, Lisa Rybicki, Brad Pohlman, Robert Dean, John William Sweetenham, Steven Andresen, Ronald Sobecks, Mikkael A. Sekeres, Anjali Advani, Randall Davis, Stacey Brown, Brian Bolwell
Journal: Blood (2006)
A phase I dose escalation trial of PT2385, a first-in-class oral HIF-2a inhibitor, in patients with advanced clear cell renal cell carcinoma.
Authors: Kevin Dale Courtney, Jeffrey R. Infante, Elaine Tat Lam, Robert A. Figlin, Brian I. Rini, James Brugarolas, Naseem J. Zojwalla, Keshi Wang, Eli Wallace, John A. Josey, Toni K. Choueiri
Journal: Journal of Clinical Oncology (2016)

2506 Background: Inactivation of the von Hippel Lindau (VHL) tumor suppressor occurs in the majority of clear cell renal cell carcinomas (ccRCC). VHL deficiency stabilizes the transcription factor hypoxia-inducible factor (HIF)-2a, an oncogenic driver of ccRCC. PT2385 is a first-in-class, orally administered selective small molecule inhibitor of HIF-2a that disrupts the heterodimerization of HIF-2a with HIF-1b and blocks the transcription of several genes involved in oncogenesis. PT2385 demonstrated anti-tumor efficacy in mouse xenograft models of ccRCC. Methods: Patients (pts) with advanced ccRCC and at least one prior therapy with a VEGF inhibitor were treated with PT2385 twice daily (BID) in a 3+3 Phase I design to determine the recommended Phase II dose (RP2D) and evaluate safety, pharmacokinetics (PK) and pharmacodynamics (PD). Plasma PK were measured on days 1 and 15 and PD weekly. Results: 26 pts were enrolled in dose escalation receiving PT2385 from 100 to 1800 mg BID. Median number of prior therapies was 4. No dose limiting toxicities were observed. Exposure generally increased with dose up to the 800 mg cohort without a further increase from 800 to 1800 mg. At 800 mg, PT2385 was rapidly absorbed (Tmax = 2 h) with a Cmax of 3.1 mg/mL and a half-life of 17 h. Targeted Cmin of 280 ng/mL was exceeded in 15/16 pts receiving ≥ 800 mg. Circulating plasma levels of the HIF-2a transcriptional target erythropoietin (EPO) rapidly decreased within 24 hrs in 15/16 pts receiving ≥ 800 mg and remained suppressed during the 16 wk sampling period. Based on safety, PK, and EPO PD data, 800 mg BID was selected as the RP2D. An additional 17 of 25 planned patients have been enrolled in an expansion cohort. Among the 43 pts, the most common all-grade adverse events (AEs) were anemia (14), fatigue (13) and peripheral edema (10). Grade ≥ 3 treatment related AE’s were anemia (3), pulmonary embolism (1), and lymphopenia (1). To date, 1 CR, 1 PR, and 24 SD have been observed—of these pts, 7 are ongoing > 7 months. Conclusions: Continuous PT2385 administration was safe and tolerable and demonstrated early evidence of clinical activity in heavily pre-treated pts with advanced ccRCC. Clinical trial information: NCT02293980.
Subcutaneous PAD As Induction Therapy for Patients with Newly Diagnosed Myeloma: A Phase 2 Trial Assessing the Impact of Minimal Residual Disease (MRD) in Patients with Deferred Autologous Stem Cell Transplantation (PADIMAC)
Authors: Rakesh Popat, James D Cavenagh, Roger G Owen, Matthew Streetly, Stephen A Schey, Mickey Koh, Josephine Crowe, Michael F. Quinn, Shirley D'Sa, Andres Virchis, Gordon Cook, Charles Crawley, Guy Pratt, Mark Cook, Heather E. Oakervee, Nicholas Counsell, Toyin Adedayo, Alison Evans, Nivette Braganca, Paul Smith, Janet lyons-Lewis, Neil Rabin, Kwee L Yong
Journal: Blood (2014)
The long noncoding RNA Tug1 connects metabolic changes with kidney disease in podocytes
Authors: Szu Yuan Li, Katalin Susztak
Journal: Journal of Clinical Investigation (2016)

An increasing amount of evidence suggests that metabolic alterations play a key role in chronic kidney disease (CKD) pathogenesis. In this issue of the JCI, Long et al. report that the long noncoding RNA (lncRNA) taurine-upregulated 1 (Tug1) contributes to CKD development. The authors show that Tug1 regulates mitochondrial function in podocytes by epigenetic targeting of expression of the transcription factor PPARγ coactivator 1α (PGC-1α, encoded by Ppargc1a). Transgenic overexpression of Tug1 specifically in podocytes ameliorated diabetes-induced CKD in mice. Together, these results highlight an important connection between lncRNA-mediated metabolic alterations in podocytes and kidney disease development.
Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease-Modifying Antirheumatic Drug Treatment
Authors: Roy Fleischmann, Michael Schiff, Désirée van der Heijde, Cesar Ramos‐Remus, Alberto Spindler, Marina Stanislav, Cristiano A. F. Zerbini, Sirel Gurbuz, Christina Dickson, Stephanie de Bono, Douglas Schlichting, Scott Beattie, Wen‐Ling Kuo, Terence Rooney, William Macias, Tsutomu Takeuchi
Journal: Arthritis & Rheumatology (2016)

Objective We undertook this phase III study to evaluate baricitinib, an orally administered JAK‐1/JAK‐2 inhibitor, as monotherapy or combined with methotrexate (MTX) compared to MTX monotherapy in patients with active rheumatoid arthritis (RA) who had received no or minimal conventional synthetic disease‐modifying antirheumatic drugs (DMARDs) and who were naive to biologic DMARDs. Methods A total of 588 patients were randomized 4:3:4 to receive MTX monotherapy (once weekly), baricitinib monotherapy (4 mg once daily), or the combination of baricitinib and MTX for 52 weeks. The primary end point assessment was a noninferiority comparison of baricitinib monotherapy to MTX monotherapy based on the proportion of patients meeting the American College of Rheumatology 20% improvement criteria (achieving an ACR20 response) at week 24. Results The study met its primary objective. Moreover, baricitinib monotherapy was found to be superior to MTX monotherapy at week 24, with a higher ACR20 response rate (77% versus 62%; P ≤ 0.01). Similar results were observed for combination therapy. Compared to MTX monotherapy, significant improvements in disease activity and physical function were observed for both baricitinib groups as early as week 1. Radiographic progression was reduced in both baricitinib groups compared to MTX monotherapy; the difference was statistically significant for baricitinib plus MTX. The rates of serious adverse events (AEs) were similar across treatment groups, while rates of some treatment‐emergent AEs, including infections, were increased with baricitinib plus MTX. Three deaths were reported, all occurring in the MTX monotherapy group. Malignancies, including nonmelanoma skin cancer, were reported in 1 patient receiving MTX monotherapy, 1 receiving baricitinib monotherapy, and 4 receiving baricitinib plus MTX. Conclusion Baricitinib alone or in combination with MTX demonstrated superior efficacy with acceptable safety compared to MTX monotherapy as initial therapy for patients with active RA.
Open-Label Bendamustine for Pediatric Patients with Relapsed or Refractory Acute Leukemia: Safety and Efficacy Outcomes,
Authors: Christopher Fraser, Patrick A. Brown, Gail C. Megason, Hyo Seop Ahn, Bin Cho, Ivan I. Kirov, Lawrence S. Frankel, Richard Aplenc, Debra M. Bensen-Kennedy, Mihaela C. Munteanu, Jennifer Weaver, Paul Harker-Murray
Journal: Blood (2011)
High dose ifosfamide in metastatic high-grade osteosarcoma, after failure of standard multimodal chemotherapy.
Authors: Emanuela Palmerini, Piero Picci, Emanuela Marchesi, Eric L. Staals, Marilena Cesari, Alessandra Longhi, Anna Paioli, Daniel Vanel, Alessandro Comandone, Davide Maria Donati, Stefano Ferrari
Journal: Journal of Clinical Oncology (2015)

10527 Background: Although there are many reports on post-relapse survival for osteosarcoma,studies on validated clinical outcome measures (progression-free survival at 6 months [6-mo PFS], complete response [CR], partial response [ PR], stable disease [SD]) are lacking. We explored high dose ifosfamide (HDIFO) activity in patients (pts) with relapsed osteosarcoma. Methods: Pts progressing after standard treatment and with measurable disease were eligible. Treatment consisted of ifosfamide 3 gr/m2/day, day 1–5, continuous infusion, every 21 days, until progression or unacceptable toxicity. Overall response rate (ORR: CR + PR), SD, 6-mo PFS, and overall survival (OS) were assessed. Results: Fifty-one pts were enrolled. Median age was 19 (7-68): 21 pts pediatric, 30 pts adult. Female/Male: 18/33. Forty-eight pts were ECOG 0, 3 pts ECOG 1. Line of treatment: 46 pts were in 1stline; 5 pts in ≥ 2nd line. 32/51 had already been treated with lower doses of ifosfamide for the primary tumor. Pattern of metastases: 35 pts lung only, 13 multiple sites, 3 bone only. 23/51 patients underwent metastasectomy after HDIFO, achieving surgical complete remission (CR2). ORR: CR: 0/51, PR: 11/51 (22%); SD 28/51 (55%), progressive disease (PD) 12/51 (23%). Median duration of response was 6 months (range: 0-192 months). PRs were mainly observed in pediatric pts (9/21 [43%]) and in pts with lung only disease (9/35 [26%]). 6-mo PFS rate was 53%. 6-mo PFS was significantly better for pts receiving HDIFO in 1stline (6-mo PFS: 1stline 52% vs ≥ 2nd line 0%; p= 0.04), while there was no difference according to age, gender or pattern of metastases. 1- and 2-year OS were 60% and 31%, respectively, with increased survival for non-progressing pts (1-year OS: PD 25% vs SD 40% vs PR 45%; p= 0.001), and for pts undergoing metastasectomy (1-year OS: CR2 96% vs no CR2 33%, p 0.0001). Conclusions: HDIFO demonstrated activity in osteosarcoma, especially in 1st line, pediatric pts and lung only disease. This series also confirms the important role of surgical complete remission in this subset of pts.
Haplo-Cord Transplantation Vs Unrelated Donor Stem Cell Transplantation in Patients with AML/MDS Older Than 50
Authors: Joanna Rhodes, Koen van Besien, Hongtao Liu, Usama Gergis, Stephanie B. Tsai, Sebastian Mayer, Wendy Stock, Richard A. Larson, Tsiporah B. Shore, Olatoyosi Odenike, Roger Pearse, Lucy A Godley, Tomer M Mark, Justin Kline, Michael R. Bishop, Andrew S. Artz
Journal: Blood (2014)
GW27-e0479 Unexpected Effect of Evacetrapib on Simvastatin Pharmacokinetics in Healthy Chinese Subjects
Authors: Yan Liang, Yimin Cui, Ellen A. Cannady, David S. Small, Ping Xin, Ming-Dauh Wang, Jian Jun Jin, Xia Zhao, Jeffrey G. Suico
Journal: Journal of the American College of Cardiology (2016)
TCT-566 Cost-Effectiveness Of The Xience™ Cobalt Chromium Everolimus Eluting Stent Compared With Bare Metal Stents: A United States Payer Perspective
Authors: Nicole Ferko, Giuseppe Ferrante, James T. Hasegawa, Tanya Schikorr, Ireena M. Soleas, Lisa M. Bernard, Marco Valgimigli
Journal: Journal of the American College of Cardiology (2015)
Immunological Responses in CLL Patients Vaccinated with Autologous Dendritic Cells Loaded with Apoptotic Bodies (Apo-DC).
Authors: Aniruddha Choudhury, Marzia Palma, Lotta Hansson, Karin Widen, Ingrid Eriksson, Barbro Nasman-Glaser, Lars Adamson, Anders Osterborg, Håkan Mellstedt
Journal: Blood (2007)
Control of Oxidant-Stress and Inflammation by Iron Chelators Deferasirox (ICL670) or Deferoxamine in β-Thalassemia: An Ancillary Study of the Novartis CICL670A0107 Trial.
Authors: Patrick Walter, Eric Macklin, John Porter, Patricia Evans, Tom Coates, Nancy F. Olivieri, Patricia Giardina, Janet Kwiatkowski, Ellis Neufeld, Bruce Ames, Jaymes Holland, Peter Marks, Elliott Vichinsky, Paul Harmatz
Journal: Blood (2005)
Acylcarnitines Are Novel Anticoagulant Lipids That Target Factor Xa and That Are Reduced in Plasma of Venous Thrombosis Patients Based on Untargeted and Targeted Metabolomics
Authors: Hiroshi Deguchi, Yajnavalka Banerjee, Gary Siuzdak, Sunia Trauger, Ewa Kalisiak, Jose A. Fernandez, Linh Hoang, Minerva Tran, Subramanian Yegneswaran, Darlene J Elias, John H. Griffin
Journal: Blood (2014)
Characterization of Waldenström Macroglobulinemia Subtypes using Global Gene Expression Profiling.
Authors: Tae-Hoon Chung, Seungchan Kim, Angela S. Baker, Tammy Price-Troska, Ruifang Xu, Irene Ghobrial, Philip R. Greipp, S. Vincent Rajkumar, Morie A. Gertz, Scott A. Van Wier, Gregory J. Ahmann, John Carpten, Rafael Fonseca
Journal: Blood (2004)
Chemokine Receptor Gene Polymorphisms and Severity of Acute Graft-Versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation from Sibling Donors.
Authors: Vinod Pullarkat, Jiyao Sun, Fangxin Hong, Ryotaro Nakamura, Lan-Feng Cao, Joycelynn Palmer, Stephen J. Forman, David Senitzer
Journal: Blood (2007)
Mature results from ABCSG-12: Adjuvant ovarian suppression combined with tamoxifen or anastrozole, alone or in combination with zoledronic acid, in premenopausal women with endocrine-responsive early breast cancer.
Authors: M. Gnant, B. Mlineritsch, H. Stoeger, G. Luschin-Ebengreuth, S. Poestlberger, P. C. Dubsky, R. Jakesz, C. F. Singer, H. Eidtmann, R. Greil
Journal: Journal of Clinical Oncology (2010)

533 Background: The ABCSG-12 trial examined the efficacy of ovarian suppression using goserelin in combination with anastrozole (ANA) or tamoxifen (TAM) ± zoledronic acid (ZOL) in premenopausal patients (pts) with endocrine-responsive breast cancer (EBC). The first efficacy analysis at ASCO 2008, showed no difference between TAM and ANA, but adding ZOL significantly reduced the risk of disease-free survival (DFS) events by 36% (p = 0.01). Longer follow-up is now available. Methods: 1,803 premenopausal pts with EBC were randomized to goserelin (3.6 mg q 28 d) and TAM (20 mg/d) or ANA (1 mg/d) ± ZOL (4 mg q 6 mo). Endpoints were DFS and overall survival (OS); both were analyzed using log-rank test and Cox models. Compared with 2008 data, we now report on 34% more DFS events and 55% more deaths, based on a December 1, 2009, data cutoff. Results: With a median follow-up of 62 mo, 183 DFS events and 65 deaths were reported. Overall, ZOL reduced the risk of DFS events by 32% (HR = 0.68 [95% CI = 0.51, 0.91]; p = 0.009). The risk reduction by ZOL was identical in the TAM and ANA strata (HR = 0.68 [0.44, 1.05] for TAM, HR = 0.68 [0.45, 1.02] for ANA), and for N– and N+ pts. With respect to OS, ZOL reduced the risk of death by 34% (HR = 0.66 [0.41, 1.09]; 0 = 0.10). The OS benefit was even more pronounced in the N+ subgroup (HR = 0.61; p= NS). There was no difference in DFS between pts who received TAM alone vs ANA alone (HR = 1.11 [0.84, 1.50]; P = .44). However, ANA pts did worse with respect to OS (HR = 1.74 [1.05, 2.87]; p = 0.03) vs TAM, probably due to differences in post-relapse treatment. Treatments were generally well tolerated. There was no case of renal failure or osteonecrosis of the jaw (ONJ). Conclusions: With longer follow-up of ABCSG-12, the addition of ZOL (4 mg q 6 mo) consistently improves both DFS and OS in the ANA and TAM subgroups, and in N+ and N– pts. There was no DFS difference between ANA and TAM, but ANA pts had inferior OS vs TAM; probably because ANA pts lack palliative aromatase inhibitor treatment. Based on these results and the known anticancer activity of adjuvant ZOL, this treatment should be considered for premenopausal pts with EBC. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration AstraZeneca, Novartis, Pfizer, Roche, sanofi-aventis Amgen, AstraZeneca, Novartis, Pfizer, Roche, sanofi-aventis, Schering-Plough AstraZeneca, Novartis
TCT-805 Intravascular Ultrasound Utilization And In-hospital Outcomes In Peripheral Vascular Interventions: Insights From Nationwide Inpatient Sample
Authors: Shilpkumar Arora, Nilay Patel, Nileshkumar J. Patel, Sidakpal S. Panaich, Achint Patel, Sopan Lahewala, Chirag Savani, Badal Thakkar, Parth Bhatt, Sanskruti Patel, Samir Patel, Vikas Singh, Ankit Chothani, Apurva Badheka, Abhishek J. Deshmukh
Journal: Journal of the American College of Cardiology (2015)
Feasibility Study of Temozolomide Maintenance Therapy in Elderly Patients with AML Following Induction Therapy with High Dose Mitoxantrone and High Dose Ara-C.
Authors: Sreedhar Katragadda, Muhammad Arshad, Delong Liu, Nasir Ahmed, Quihu Shi, Tauseef Ahmed, Karen Seiter
Journal: Blood (2006)
Survival and Predictors of Outcome in Acute Leukemia Patients Admitted to the Intensive Care Unit.
Authors: Snehal G. Thakkar, Zachariah A. McIver, Sanjay R. Mohan, Giridharan Ramsingh, Anjali S. Advani, Ronald Sobecks, Lisa Rybicki, Alejandro Arroliga, Matthew Kalaycio, Mikkael A. Sekeres
Journal: Blood (2005)
High doses of recombinant erythropoietin alfa for myelodysplastic syndromes: High incidence of responses in patients with low pre-treatment serum erythropoietin concentrations
Authors: None Finelli, E. Vigna, C. Bosi, J. El-Cheikh, G. Martinelli, M. Malagola, M. Rondoni, M. Baccarani
Journal: Journal of Clinical Oncology (2004)

6683 Background: Severe symptomatic anemia is common in patients (pts) with myelodysplastic syndromes (MDS). Recombinant human erythropoietin (rHuEPO), at a dosage of 30–70.000 U/week, has proven effective in 20–30 % of cases. Recently, a different schedule of rHuEPO administration (40.000 U twice weekly) has shown to be effective in lymphoid malignancies and solid tumors. Methods: From September 2001, 18 pts with low-or-intermediate risk MDS were treated with rHuEPO alfa because of symptomatic anemia (Hb < 10 g/dl). The pts received a high doses rHuEPO regimen: 40.000 U twice weekly, for the first month, followed by a single weekly dose of 40.000 as maintenance treatment, for at least 8 weeks. Only pts with a pre-treatment serum EPO < 200 U/l were selected for rHuEPO treatment Results: 7 pts have a follow-up < 2 months, and are still under evaluation. All the 11 valuable pts (6 males, median age: 72, range 35–81 yrs), showed a favourable response. 4 pts were transfusion-dependent. Among them, 2 pts no more required transfusions, 2 showed a > 50% decrease of their transfusion need, and 7 pts showed a > 1g/dl increase of Hb. The median duration of response was of 11 (2–22) months, and 8 pts are still maintaining response. Conclusions: rHuEPO is expensive, and a favourable response is achieved in 20–30 % of the overall MDS population. However, if pts are carefully selected on the basis of a low (< 200 U/l) pre-treatment serum EPO level, ad if high doses (40.000 U twice weekly) are initially administered, the percentage of responses might be very high. No significant financial relationships to disclose.
GW27-e0271 A study on the mechanism of the oxidative damage in Ginsenoside Rb1 against the intrinsic aging of mouse brain
Authors: Bin Zhou, Shujie Yu, Xianguan Yu, Yong Liu, Dinghui Liu, Lin Wu, Min Wang, Yesheng Ling, Baoshun Hao, Lin Chen, Xiaoxian Qian
Journal: Journal of the American College of Cardiology (2016)
R-Vemp Is a Safe and Effective Chemo-Immunotherapeutic Regimen In Elderly Unfit DLBCL Patients: Report From a Single Center-Experience
Authors: Francesca Pavanello, Antonio Branca, Anna Colpo, Marco Pizzi, Rocco Cappellesso, Ilaria Gianesello, Elena De March, Livio Trentin, Gianpietro Semenzato, Francesco Piazza
Journal: Blood (2013)
Epitope-Specific Typing (EST) for HLA-DPB1 Matching: Proof of Principle for an Innovative Approach to Unrelated Hematopoietic Stem Cell Donor Selection.
Authors: Elisabetta Zino, Luca Vago, Simona Di Terlizzi, Benedetta Mazzi, Luigi D’ Amato, Silvano Rossini, Fabio Ciceri, Maria G. Roncarolo, Claudio Bordignon, Katharina Fleischhauer
Journal: Blood (2006)